Veristat’s Bold Thinking and World Class Clinical, Regulatory and Commercialization Capabilities Allow the Company to Successfully Tackle Complex Therapy Development Challenges to Meet the Goals of its Clients
Veristat congratulates Awakn for being awarded UK State Funding to Identify Optimal Pathway to Market In UK & US For Its Lead Clinical Development Program – Ketamine-Assisted Therapy For Alcohol Use Disorder
Instrumental to Veristat’s growth, success, and client satisfaction over the last 15 years
Providing sponsors expert staff to accelerate milestones and support study success
Acquires Swiss-based multi-disciplinary consultancy SFL (Solutions for Life Sciences) to accelerate the development of and access to innovative treatments
Accomplished Financial Executive to Drive Company’s Next Phase of Growth
Bridging the Gap between Trial and Treatment by Supporting the Approval of Several Novel Therapies for Rare Diseases
Acquires Drug Development and Regulation (DDR), a
regulatory consultancy led by former senior officer at
European Medicines Agency (EMA)
Global Talent Executive to Advance Company’s Commitment to a Best-in-class Workforce